RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biohaven Pharmaceutical Holding Company Stock

Biohaven Pharmaceutical Holding Company Revenue 2024

Biohaven Pharmaceutical Holding Company Revenue

8.5 M USD

Ticker

BHVN

ISIN

VGG111961055

WKN

A2DQ7W

In 2024, Biohaven Pharmaceutical Holding Company's sales reached 8.5 M USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Biohaven Pharmaceutical Holding Company Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e1.4924,89
2028e0.941,13
2027e0.4583,06
2026e0.06645,64
2025e0.022234,14
2024e0.014362,88
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--

Biohaven Pharmaceutical Holding Company Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biohaven Pharmaceutical Holding Company, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biohaven Pharmaceutical Holding Company from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biohaven Pharmaceutical Holding Company’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biohaven Pharmaceutical Holding Company. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biohaven Pharmaceutical Holding Company’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biohaven Pharmaceutical Holding Company’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biohaven Pharmaceutical Holding Company’s growth potential.

Biohaven Pharmaceutical Holding Company Revenue, EBIT and net profit per share

DateBiohaven Pharmaceutical Holding Company RevenueBiohaven Pharmaceutical Holding Company EBITBiohaven Pharmaceutical Holding Company Net Income
2029e1.49 B undefined0 undefined323.04 M undefined
2028e901.55 M undefined-82.13 M undefined-23.14 M undefined
2027e446.49 M undefined-451.31 M undefined-267.11 M undefined
2026e57.44 M undefined-620.41 M undefined-578.83 M undefined
2025e16.6 M undefined-659.88 M undefined-645.72 M undefined
2024e8.5 M undefined-642.18 M undefined-863.19 M undefined
20230 undefined-436.05 M undefined-408.17 M undefined
20220 undefined-567.93 M undefined-570.28 M undefined
20210 undefined-218.9 M undefined-213.8 M undefined
20200 undefined-114.51 M undefined-118.67 M undefined
20190 undefined-374.12 M undefined-528.8 M undefined
20180 undefined-224.55 M undefined-240.92 M undefined
20170 undefined-107.58 M undefined-139.2 M undefined
20160 undefined-60.63 M undefined-63.68 M undefined
20150 undefined-9.7 M undefined-10.06 M undefined
20140 undefined-1.48 M undefined-1.46 M undefined

Biohaven Pharmaceutical Holding Company stock margins

The Biohaven Pharmaceutical Holding Company margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biohaven Pharmaceutical Holding Company. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biohaven Pharmaceutical Holding Company.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biohaven Pharmaceutical Holding Company's sales revenue. A higher gross margin percentage indicates that the Biohaven Pharmaceutical Holding Company retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biohaven Pharmaceutical Holding Company's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biohaven Pharmaceutical Holding Company's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biohaven Pharmaceutical Holding Company's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biohaven Pharmaceutical Holding Company. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biohaven Pharmaceutical Holding Company's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biohaven Pharmaceutical Holding Company Margin History

Biohaven Pharmaceutical Holding Company Gross marginBiohaven Pharmaceutical Holding Company Profit marginBiohaven Pharmaceutical Holding Company EBIT marginBiohaven Pharmaceutical Holding Company Profit margin
2029e0 %0 %21.68 %
2028e0 %-9.11 %-2.57 %
2027e0 %-101.08 %-59.83 %
2026e0 %-1,080.15 %-1,007.74 %
2025e0 %-3,975.43 %-3,890.1 %
2024e0 %-7,555.09 %-10,155.21 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %

Biohaven Pharmaceutical Holding Company Aktienanalyse

What does Biohaven Pharmaceutical Holding Company do?

Biohaven Pharmaceutical is a biopharmaceutical company focused on developing innovative therapies for neurological disorders. It was founded in 2013 and is headquartered in New Haven, Connecticut. The company's business model is based on discovering and developing novel medications for conditions such as migraine, spinal muscular atrophy, Alzheimer's, and other neurological disorders. Biohaven invests in research and development to create therapies that can enhance patients' lives. It has divisions dedicated to developing treatments for migraine, neurodegeneration, and spinal muscular atrophy. Biohaven's first product, Rimegepant, is a migraine medication that inhibits the CGRP receptor. It has been approved in the US for migraine treatment. Troriluzol, another migraine medication, is still in clinical development. Biohaven is also active in the fields of Alzheimer's and ALS, with medications like BHV-0223 and BHV-4157 in development. The company aims to develop innovative medications that can improve and restore patient health. It collaborates with other companies and research institutions to maximize its research potential and bring innovative therapies to market faster. Overall, Biohaven Pharmaceutical is a leading biopharmaceutical company dedicated to developing innovative therapies for neurological disorders, with a strong pipeline of medications and a committed research and development department working towards improving global patient healthcare. Biohaven Pharmaceutical Holding Company ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Biohaven Pharmaceutical Holding Company's Sales Figures

The sales figures of Biohaven Pharmaceutical Holding Company originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Biohaven Pharmaceutical Holding Company’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Biohaven Pharmaceutical Holding Company's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Biohaven Pharmaceutical Holding Company’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Biohaven Pharmaceutical Holding Company stock

How much revenue did Biohaven Pharmaceutical Holding Company generate this year?

Biohaven Pharmaceutical Holding Company has achieved a revenue of 8.5 M USD this year.

How much was the turnover of the company Biohaven Pharmaceutical Holding Company compared to the previous year?

The revenue of Biohaven Pharmaceutical Holding Company has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Biohaven Pharmaceutical Holding Company?

The revenue of Biohaven Pharmaceutical Holding Company is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Biohaven Pharmaceutical Holding Company measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Biohaven Pharmaceutical Holding Company so important for investors?

The revenue of Biohaven Pharmaceutical Holding Company is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Biohaven Pharmaceutical Holding Company pay?

Over the past 12 months, Biohaven Pharmaceutical Holding Company paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biohaven Pharmaceutical Holding Company is expected to pay a dividend of 0 USD.

What is the dividend yield of Biohaven Pharmaceutical Holding Company?

The current dividend yield of Biohaven Pharmaceutical Holding Company is .

When does Biohaven Pharmaceutical Holding Company pay dividends?

Biohaven Pharmaceutical Holding Company pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biohaven Pharmaceutical Holding Company?

Biohaven Pharmaceutical Holding Company paid dividends every year for the past 0 years.

What is the dividend of Biohaven Pharmaceutical Holding Company?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biohaven Pharmaceutical Holding Company located?

Biohaven Pharmaceutical Holding Company is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biohaven Pharmaceutical Holding Company kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biohaven Pharmaceutical Holding Company from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Biohaven Pharmaceutical Holding Company pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Biohaven Pharmaceutical Holding Company in the year 2023?

In the year 2023, Biohaven Pharmaceutical Holding Company distributed 0 USD as dividends.

In which currency does Biohaven Pharmaceutical Holding Company pay out the dividend?

The dividends of Biohaven Pharmaceutical Holding Company are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biohaven Pharmaceutical Holding Company

Our stock analysis for Biohaven Pharmaceutical Holding Company Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biohaven Pharmaceutical Holding Company Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.